跳转至内容
Merck
CN
所有图片(1)

主要文件

SML0702

Sigma-Aldrich

MRT67307 盐酸盐

≥98% (HPLC)

别名:

N-[3-[[5-环丙基-2-[[3-(4-吗啉基甲基)苯基] 氨基]-4-嘧啶基] 氨基] 丙基]-环丁基甲酰胺 盐酸盐

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C26H36N6O2 · xHCl
分子量:
464.60 (free base basis)
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

方案

≥98% (HPLC)

表单

powder

储存条件

desiccated

颜色

white to light brown

溶解性

H2O: 15 mg/mL, clear

储存温度

2-8°C

SMILES字符串

N5(CCOCC5)Cc1cc(ccc1)Nc2nc(c(cn2)C4CC4)NCCCNC(=O)C3CCC3

InChI

1S/C26H36N6O2/c33-25(21-5-2-6-21)28-11-3-10-27-24-23(20-8-9-20)17-29-26(31-24)30-22-7-1-4-19(16-22)18-32-12-14-34-15-13-32/h1,4,7,16-17,20-21H,2-3,5-6,8-15,18H2,(H,28,33)(H2,27,29,30,31)

InChI key

UKBGBACORPRCGG-UHFFFAOYSA-N

应用

MRT67307 盐酸盐已用于研究其对 LPS(脂多糖)诱导溶酶体管状结构的影响。

生化/生理作用

MRT67307 是 IKKe 和 TBK-1 的双重抑制剂。
MRT67307 是 IKKe 和 TBK-1 的双重抑制剂。IKKe 和 TBK-1 介导干扰素调节因子 3 (IRF3) 的磷酸化。
MRT67307 是氨基嘧啶衍生物,IC 50 值为 19。已知其可诱导 TLR(toll 样受体)介导的抗炎细胞因子生成。此外,MRT67307 还可预防促炎相关细胞因子的分泌。

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Zachary P Guinn et al.
Immunobiology, 224(4), 565-574 (2019-05-11)
IFN-γ produced during viral infections activates the IFN-γ receptor (IFNGR) complex for STAT1 transcriptional activity leading to expression of Interferon Regulatory Factors (IRF). Simultaneous activation of TBK/IKKε via TLR3 during viral infections activates the transcription factor IRF3. Together these transcription factors
Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies.
Hasan M and Nan Y
Pharmacological Research, 111, 336-342 (2016)
Daniel P.
The Inhibitor Index: A Desk Reference on Enzyme Inhibitors, Receptor Antagonists, Drugs, Toxins, Poisons, Biologics, and Therapeutic Leads (2017)
mTOR controls lysosome tubulation and antigen presentation in macrophages and dendritic cells.
Saric A, et al.
Molecular Biology of the Cell, 27(2), 321-333 (2016)
Nadia Carvalho Lima et al.
International journal of molecular sciences, 21(9) (2020-05-07)
Selective FGFR inhibitors such as infigratinib (BGJ398) and erdafitinib (JNJ-42756493) have been evaluated in clinical trials for cancers with FGFR3 molecular alterations, particularly in urothelial carcinoma patients. However, a substantial proportion of these patients (up to 50%) display intrinsic resistance

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门